Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

China's Waterstone Pharma In-licenses Hepatitis C Drug from SCYNEXIS

publication date: Nov 4, 2014
Waterstone Pharmaceutical of Wuhan, China obtained global rights to a treatment for chronic viral infections from SCYNEXIS, a North Carolina anti-infectives company. The drug, SCY-635, has completed a Phase II trial in patients with hepatitis C. Waterstone, which describes itself as an international company with its main operations in China, develops novel drugs for liver and gastrointestinal diseases. The company is backed by well-known investors including BAR Capital, CID Group, OrbiMed and Acorn Camps. More details....

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital